Celgro technology is a next-generation collagen-based scaffold to support tissue growth and repair
Singapore: Australia's regenerative medicine company, Orthocell, has recieved Chinese patent for its Collagen Scaffold for cell growth, the biological materials to repair damaged soft tissue.
"This comes at a perfect time for the company as we move our products through international registration processes," said Mr Paul Anderson, managing director, Orthocell said.
Orthocell's novel methodology for producing a bio-scaffold device overcomes or alleviates some of the major problems associated with other currently available bio-scaffolds which can include poor surface chemistry which provides suboptimal attachment of cells, acidic by-products which degrade the local pH such that cell micro-environments are disrupted, immune reactions due to presence of residual foreign cells from the host and the lack of suitable pore size and structure and lack of sufficient mechanical properties required to withstand the harsh environments in which bio-scaffolds are regularly used.
The company's Celgro technology is a next-generation collagen-based scaffold to support tissue growth and repair.
